Design and evaluation of buccal adhesive hydrocortisone acetate (HCA) tablets.
Many studies have shown that topical buccal therapy with steroid anti-inflammatory drugs is useful in controlling ulcerative and inflammatory mucosal diseases. This local treatment is based on the concept that a high activity of steroids can be produced at the site of administration and, at the same time, the degree of systemic side effects can be minimized or avoided. In this study we developed a new formulation consisting of a mucoadhesive tablet formulation for buccal administration of hydrocortisone acetate (HCA). Three types of tablet were developed containing three mucoadhesive components: hydroxypropylmethyl cellulose (Methocel K4M), carboxyvinyl polymer (Carbopol 974P), and polycarbophyl (Noveon AA1); the first polymer is a cellulose derivative, the others are both polyacrylic acid derivatives. For each of those, three tablet batches were produced changing the quantity of the mucoadhesive component (10, 20, and 30%), resulting in 9 different formulations. The compatibility of HCA with all excipients using Differential Scanning Calorimetry (DSC) was assessed. Tablets were manufactured by wet granulation followed by compression. Technological controls on granulates (Hausner index, Carr index, granulometry and Karl-Fischer percentage humidity) and tablets (thickness, diameter, friability, hardness, uniformity of content, weigh uniformity and dissolution kinetic) were carried out. Mucoadhesion properties, ex vivo permeability through porcine buccal mucosa, in vivo behavior and compliance were evaluated. Technological controls have demonstrated that the increase in the (percentage) of mucoadhesive causes an increase in granulometry followed by a reduction in the granulate flowability, however all the tablets have given satisfactory technological results and conformed to the 3rd Ed. European Pharmacopoeia specifications. Mucoadhesion, ex vivo permeability and in vivo behavior results notably differed among tablets, depending on the quality and quantity of the mucoadhesive component. An overall comparison of results showed the tablets containing Carbopol 20% resulted to be the best formulation among those developed.
Ceschel
G C
GC
Pharmaceutical Sciences Department Bologna University, Italy. paolam@biocfarm.unibo.it
Maffei
P
P
Lombardi Borgia
S
S
Ronchi
C
C
D000179:Acrylates; D000180:Acrylic Resins; D000268:Adhesiveness; D000269:Adhesives / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use; D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000737:chemistry* / Q000494:pharmacology; D002626:Chemistry, Pharmaceutical / Q000379:methods; D003781:Denture Retention; D004337:Drug Carriers; D015195:Drug Design; D006801:Humans; D006854:Hydrocortisone / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology; D008747:Methylcellulose; D009059:Mouth Diseases / Q000628:therapy; D009061:Mouth Mucosa / Q000187:drug effects; D012995:Solubility; D013607:Tablets
D000179:Acrylates; D000180:Acrylic Resins; D000269:Adhesives; D000893:Anti-Inflammatory Agents; D004337:Drug Carriers; D013607:Tablets; C117167:carbopol 974P NF; C021650:hydrocortisone acetate; C030312:calcium polycarbophil; D008747:Methylcellulose; D006854:Hydrocortisone